Kornimate/medical-research-clean huggingface dataset:
sero-epidemiological study of the sars-cov-2 virus responsible for covid-19 in france

Conditions: SARS (Severe Acute Respiratory Syndrome); COVID-19

Summary: on january 2020, the discovery of a new coronavirus (sars-cov-2) was officially announced by the chinese health authorities and the world health organization (who). its complete genome was sequenced by the laboratory of respiratory infection viruses at the institut pasteur on 29 january 2020 in france. this will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests. many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. serological studies can provide answers to these questions. there is no serological test for sars-cov-2 yet, but the laboratory of respiratory infection viruses at the institut pasteur is working on its development. this study proposes to carry out a collection of samples taken from subjects who travelled to china before the epidemic outbreak or suspected of being infected with sars-cov-2. as soon as it is available, serology will be performed on the collected samples.

on january 2020, the discovery of a new coronavirus (sars-cov-2) was officially announced by the chinese health authorities and the world health organization (who). this new virus is presented as the causative agent of pneumonias. its complete genome was sequenced by the laboratory of respiratory infection viruses at the institut pasteur on 29 january 2020 in france. this will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests. many questions are being asked about this new virus and the infection it causes, including questions about the transition from animal to human occur, the beginning of viral circulation in humans, the period of contagiousness, the percentage of asymptomatic and pauci-symptomatic forms. serological studies can provide answers to these questions. there is no serological test for sars-cov-2 yet, but the laboratory of respiratory infection viruses at the institut pasteur is working on its development. this study proposes to carry out a collection of samples taken from subjects who travelled to china before the epidemic outbreak or suspected of being infected with sars-cov-2. as soon as it is available, serology will be performed on the collected samples.

Eligibility criteria:
inclusion criteria: * affiliated with or benefiting from a social security system * state of health compatible with a blood sample as defined in the protocol exclusion criteria: * person benefiting from a legal protection measure or unable to express informed consent to participation * have had an infectious episode and/or respiratory signs in the 14 days prior to the scheduled visit (corser 1 and 2a, 2b) * have been in contact with a confirmed case of sars-cov-2 infection within 14 days prior to the date of the visit.(corser 1 and 2a, 2b)
evaluation of microinjected amnion-derived collagen by dermapen in the smoothing of skin wrinkles

Conditions: Facial Wrinkles - Rough Texture - Hyperpigmentation

Summary: the aim of this work was to assess the efficacy of irradiated amniotic collagen matrix in comparison with platelet rich plasma in facial rejuvenation.the present study included 20 patients with facial wrinkles divided into 2 groups using split face technique: group (a) subjected to microneedling with amnion gel on the right side of the face . group (b) subjected to microneedling with prp on the other side of the face.according to a skin analysis camera (antera camera), there was statistically significant improvement after treatment and between both groups as regard to the roughness(texture) and melanin appeared by antera camera in which group (a) showed better improvement than group (b). also, skin biopsies showed improvement in both sides after treatment in which the epidermis was thicker, collagen bundles were broader and thicker than before treatment also elastic fibers were longer, evenly arranged and thicker than before treatment. the patients were followed up over a period of 3 months after the last session with no complications or changes were occurred and the results of sessions were maintained.


Eligibility criteria:
inclusion criteria: * patients who did not receive any treatment for aging within the last 6 months. * patients who accepted to participate in this study. exclusion criteria: * patients with bleeding, coagulation disorders, severe anemia, liver disease, renal disease, recurrent facial herpes, keloid formation, pregnant, and lactating females.
phase 4 study - mucinex d as adjunct therapy

Conditions: Acute Respiratory Infection; Bronchitis; Rhinosinusitis

Summary: the objective of the study is to evaluate the safety and efficacy of mucinex d tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.


Eligibility criteria:
inclusion criteria: * ages eligible for study: 18 to 75 years, * genders eligible for study: both * adult patients presenting at the physician's office with symptoms diagnostic for acute respiratory infection, such as bronchitis or rhinosinusitis; with a clinical diagnosis of acute respiratory infection, meeting the physician's usual diagnostic criteria in practice for prescription of oral antibiotics. * the investigator will evaluate patients on a total of seven criteria for inclusion. exclusion criteria: * have chronic, recurring respiratory signs and symptoms, such as allergic rhinitis or chronic bronchitis, which, in the investigator's opinion, would confound interpretation of symptoms ratings for the acute respiratory infection; * the investigator will evaluate patients on twelve additional criteria for exclusion.

Keywords: acute respiratory infection bronchitis rhinosinusitis
rate of postpyloric migration of spiral nasojejunal tubes in brain injured patients

Conditions: Acute Brain Injury

Summary: the success rate of unguided nasojejunal feeding tube insertion will be determined in acute brain injured patients. factors influencing tube self-progression will be evaluated.

nutrition support is important in brain injured patients. several studies have shown that small bowel feeding compared with gastric feeding may be associated with a reduction in pneumonia in critically ill patients. the canadian clinical practice guidelines recommended that small bowel feedings should be considered for patients at high risk for intolerance to enteral nutrition. there are several methods to place postpyloric tube, but there is a high success rate with endoscopic or radiological assistance. however, they are time consuming procedures, which is of limited availability at bedside and requires trained staff. nasojejunal tube with spiral end (flocare bengmark nj tube) has been used for bedside placement for 10 years. but only limited data are available for success rate, especially in brain injured patients. the aim of this study is to access the success rate and influencing factors of spiral end nasojejunal tube in such a population.

Eligibility criteria:
inclusion criteria: * acute brain injured patients admitted to neuro-icu exclusion criteria: * patients' stay in icu shorter than 3 days * patients with contraindication to naso-feeding tube placement

Keywords: nutrition enteral access
distal radius fracture: clinical outcome after conservative treatment in the elder patient

Conditions: Distal Radius Fracture

Summary: this study is performed to evaluate the outcome of conservative treatment after distal radius fractures in patients of 65 years or older at the time of the injury, primarily with respect to the prognostic value of the adolfsson-score for the functional demands of the patient on his hand.


Eligibility criteria:
inclusion criteria: * distal radius fracture with conservative treatment * treated in 2014 or 2015 * x-ray of injury * informed consent by the patient to participate in the study exclusion criteria: * no x-ray * no signed informed consent * demented patients

Keywords: adolfsson-score suhm score
the effect of laparoscopic surgery on ovarian reserve according to cyst types

Conditions: Ovarian Cysts

Summary: the aim of our study is to compare the effect of laparoscopic ovarian cystectomy on ovarian reserve in terms of different cyst types.

participants who will be treated surgically for ovarian cysts will be included in the study. anti-mullerian hormone (amh) levels of the participants will be investigated before the surgery and 6 months after the surgery. all surgeries will be performed under general anesthesia laparoscopically. after histopathological evaluation, the participants will be divided into three groups; group 1: endometrioma, group 2: mature cystic teratoma (dermoid cyst) and group 3: serous or mucinous cystadenoma. a total of fifty-five women will be included in the study.

Eligibility criteria:
inclusion criteria: * no ovarian surgery before exclusion criteria: * endocrinological pathologies * suspicion of malignancy in preoperative laboratory and ultrasonographic evaluations * detection of malignancy in histopathological examination

Keywords: ovarian reserve anti-mullerian hormone ovarian cyst
perioperative nutrition in upper gastrointestinal (gi) cancer surgery

Conditions: Stomach Neoplasms; Esophageal Neoplasms

Summary: the aim of this study is to demonstrate the influence of peri-operative nutrition on the post-operative complications, preservation of lean body mass and length of stay after gastrectomy or oesophagectomy.


Eligibility criteria:
inclusion criteria: * surgery for upper gi cancer * age over 18 * informed consent exclusion criteria: * major swallowing disorders * dementia or other psychological state precluding compliance and understanding of research protocol * pre-existing enteral or parenteral nutrition

Keywords: gastric cancer esophageal cancer surgical complications immunonutrition
dose escalated concomitant boost radiotherapy for early breast cancer

Conditions: Breast Cancer

Summary: the goal of this prospective, single-arm, phase ii, non-randomized trial is to evaluate an hypofractionation schedule with high dose simultaneous integrated tumor bed boost in early breast cancer patients. the main question\[s\] it aims to answer are: * evaluate the rate of all grades of radiation-induced fibrosis at 4 years. * evaluate poor/fair cosmesis rate participants will be treated with hypofractionated radiotherapy (rt) to whole breast with a dose of 40.05 gy in 15 fractions (2.67 gy/die) and a concomitant tumor bed dose of 52.5 gy (3.5 gy/die)

this is a prospective, single-arm, phase ii, non-randomized clinical trial that will test an hypofractionated schedule with high dose simultaneous integrated tumor bed boost set on a previous dose finding study. patients will be treated with hypofractionated rt to whole breast with a dose of 40.05 gy in 15 fractions (2.67 gy/die) and a concomitant tumor bed dose of 52.5 gy (3.5 gy/die). the study population will include early breast cancer patients with younger age (\< or= 50 years) and additional risk factors for local recurrence. the primary objective of the study is to evaluate the rate of radiation-induced fibrosis at 4 years.the expected enrollment is 132 patients in 6 years. each patient must have a minimum follow-up of 4 years. the secondary objective is to evaluate cosmesis; other objectives are to evaluate quality of life (qol) and the rate of local control.

Eligibility criteria:
inclusion criteria: * histologically proven breast cancer who have undergone conservative surgery * at least 3 inserted clips * age: from 18 years old to 50 years * at least one of the following risk factors: n1 disease, lvi, extensive intraductal component (\>25%), close margins (\<4 mm), non-hormone-sensitive disease, grading 3 * ecog performance status \< 2 * adequate bone marrow (haemoglobin concentration \> 8 g/dl, white blood cell count \> 3000/mm3, platelet count \> 75000). exclusion criteria: * previous chest radiation treatment * bilateral breast cancer * neoadjuvant chemotherapy * bmi \> 35 * collagen diseases * pregnancy or breastfeeding

Keywords: tumor bed boost radiotherapy hypofractionation
scapular positioning in standing position using sonography

Conditions: Shoulder Osteoarthritis; Arthropathy Shoulder

Summary: the objective of this study is to analyse the positioning of the scapula in standing position and compared to the supine position (ct scan) in 3 dimensions (3 rotations of the scapula) using a non-radiant, portable system, combining an ultrasound probe with marker and a camera integrated into a tablet for the three-dimensional location of the marker (probe).

this is a mono-center trial. patients in the process of pre-operative care of a reverse shoulder arthroplasty (ct scan already available as part of the care course in supine position) will be offered the study. a localizer ultrasound will be performed during surgical consultation or the day before the surgery in standing position (duration: 1/2 day). this consultation takes place during the course of the surgical consultation or when the patient is admitted the day before his surgical procedure.

Eligibility criteria:
inclusion criteria: * major patients and agreeing to participate in the study after oral and written information. * care course patients for a reverse shoulder arthroplasty on a native shoulder joint exclusion criteria: * patients under the age of 18 * patients refusing to participate in the study * patients whose condition does not allow informed consent * patients who are subject to legal protection (safeguarding of justice, curatorship, guardianship), persons deprived of their liberty * unaffiliated patients and non-beneficiaries of a health insurance plan

Keywords: reverse shoulder arthroplasty
home-based aerobic training among adolescents with chronic diseases during covid-19 pandemic

Conditions: Chronic Disease; Chronic Diseases in Adolescence; Chronic Disease of Immune System; Chronic Kidney Diseases

Summary: data show that the coronavirus disease 2019 (covid-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. in addition, the prevalence of chronic diseases among adolescents has increased in the last years. about 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. in march, 2020, the quarantine was officially implemented in sao paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. to mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.


Eligibility criteria:
inclusion criteria: diagnosed with either one of the following chronic conditions: * inflammatory bowel disease; * autoimmune hepatitis; * liver transplant; * renal transplant; * systemic lupus erythematosus; * juvenile dermatomyositis; * juvenile idiopathic arthritis. exclusion criteria: * patients with physical limitations that preclude exercise. * patients diagnosed with covid-19. * patients diagnosed with mental disorders.
bomedemstat vs hydroxyurea for essential thrombocythemia (mk-3543-007)

Conditions: Essential Thrombocythemia

Summary: the purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (et) participants for whom cytoreductive therapy is indicated. its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (dchr). the primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to dchr.


Eligibility criteria:
inclusion criteria: * diagnosis of essential thrombocythemia (et) based on world health organization criteria for myeloproliferative neoplasms, and an indication for cytoreductive therapy regardless of age or risk status * has a centrally assessed bone marrow fibrosis score of grade 0 or grade 1, as per a modified version of the european consensus criteria for grading myelofibrosis * has received no prior cytoreductive treatment for their et * human immunodeficiency virus (hiv)-infected participants have well controlled hiv on antiretroviral therapy * participants who are hepatitis b surface antigen (hbsag) positive are eligible if they have received hepatitis b virus (hbv) antiviral therapy for at least 4 weeks and have undetectable hbv viral load * participants with history of hepatitis c virus (hcv) infection are eligible if hcv viral load is undetectable exclusion criteria: * history of any illness/impairment of gastrointestinal function that might interfere with drug absorption * history of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years * hiv-infected participants with a history of kaposi's sarcoma and/or multicentric castleman's disease * has an active infection requiring systemic therapy * has had a major surgery \ 4 weeks prior to first dose

Keywords: essential thrombocythemia et bomedemstat img-7289
endoscopic complications after gastric bypass

Conditions: Obesity, Morbid; Bariatric Surgery Candidate

Summary: endoscopic complications such as gastro-esophageal reflux disease, ulcera, gastritis, bile reflux, anastomotic stricture and so on are described after gastric bypass surgery. the incidence of these complications after rygb versus mgb/oagb are getting observed.

all patients who were readmitted to our centre of excellence for obesity and metabolic surgery (october 2014 - march 2018) are observed regarding endoscopic complications in s.a. rygb and mgb/oagb.

Eligibility criteria:
inclusion criteria: * all patients who underwent rygb or mgb/oagb as a primary surgery and were readmitted to tho hospital undergoing upper endoscopy are included exclusion criteria: -
effect of the atazanavir (atv) 150l mutation on subsequent treatment response in hiv infected subjects

Conditions: HIV Infection

Summary: this study will compare the response of subjects who failed a first-line atv-containing regimen and who have the 150l-containing virus to subsequent protease inhibitor (pi)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (nnrti), and is subsequently receiving pi-containing therapy.


Eligibility criteria:
inclusion criteria: * currently on a first-line antiretroviral regimen containing atv with a confirmed rebound and a genotype that verifies the presence of an 150l mutation or on a first-line regimen containing an nnrti and pi-naive, with a confirmed rebound exclusion criteria: * women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study. * women who are pregnant or breastfeeding. * a life expectancy of \<12 months. * presence of a newly diagnosed hiv-related opportunistic infection or any other medical condition requiring acute therapy at the time of enrollment. * active alcohol or substance abuse sufficient, in the investigator's opinion, to prevent adequate adherence to study therapy or to increase the risk of developing pancreatitis or chemical hepatitis.

Keywords: treatment experienced
a study to learn how safe, tolerable and capable of producing an immune response is, a modified rna vaccine against pandemic influenza

Conditions: Grippe; Influenza; Vaccines

Summary: the purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. the study vaccine is called pandemic influenza modrna (pdmflu) vaccine. this study is seeking for participants who are: * between the ages of 18 to 49 years old or 65 to 84 years old. * willing and able to follow with all scheduled visits, treatment plan, laboratory tests, lifestyle changes, and other study procedures. * healthy as confirmed by medical history, physical examinations, and the study doctor. * capable of signing informed consent. participants will receive either: * the pdmflu vaccine, * a licensed influenza vaccine * a placebo. a placebo does not have any medicine in it but looks just like the study medicine. participants will not know which vaccine they receive. participants will receive the study vaccines as a single shot in the arm. the study will compare participant experiences to help understand if the pdmflu vaccine is safe and effective. participants will take part in this study for up to 13 months. during this time, the participants will receive the study vaccine and take part in follow-up visits.


Eligibility criteria:
key inclusion criteria: - healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. key exclusion criteria: - does not meet seasonal influenza vaccine requirements per cohort.

Keywords: flu pandemic influenza rna vaccine
a computer-based system for symptom reporting in patients with cancer undergoing treatment

Conditions: Caregiver; Malignant Neoplasm

Summary: this pilot trial studies the usability and usefulness of a computer-based system for reporting symptoms in patients with cancer undergoing treatment. cancer patients undergoing cancer treatment are not always comfortable contacting the doctor when experiencing symptoms. a computer based platform, where patients can input symptoms, may seem less intrusive than a phone call and may improve patient access to care.

primary objectives: i. to assess the usability and usefulness of a computer-based system for cancer patient symptom reporting. secondary objectives: i. to collect preliminary effectiveness data: quality of life outcomes with the function assessment of cancer therapy - general (fact-g) and self-efficacy as measured by chronic disease self-efficacy scale, revised (cdses-r). outline: participants are randomized to 1 of 2 arms. arm i: participants receive usual care for 3 weeks, then use a computer-based symptom reporting system for 3 weeks. caregivers may assist patients in the use of the computer based symptoms reporting system. arm ii: participants use a computer-based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. caregivers may assist patients in the use of the computer based symptoms reporting system. after completing study intervention, participants are followed up for 30 days.

Eligibility criteria:
inclusion criteria: * patient: active outpatient cancer treatment (chemotherapy, immunotherapy, radiation, and hormonal therapy) * patient: no clinical evidence of cognitive or psychological impairment. * patient: home internet access on computer or phone. * caregiver: selected family member or close friend of the cancer patient matching the patient inclusion criteria outlined above. exclusion criteria: * inability to provide informed consent.